Select publications

Gandara DR et al; Southwest Oncology Group. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21(10):2004-10. Abstract

Gatzemeier U et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc ASCO 2004;Abstract 7010.

Giaccone G et al. Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmall- cell lung cancer: A phase III trial — INTACT 1. J Clin Oncol 2004;22(5):777-84. Abstract

Hanna N et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with nonsmall- cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22(9):1589-97. Abstract

Herbst RS et al. Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall- cell lung cancer: A phase III trial — INTACT 2. J Clin Oncol 2004b;22(5):785-94. Abstract

Herbst RS et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23(11):2544-55. Abstract

Herbst RS et al. TRIBUTE — A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc ASCO 2004a;Abstract 7011.

Kris MG et al. Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC). Proc ASCO 2004;Abstract 7062.

Le Chevalier T et al. Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): Cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected nonsmall cell lung cancer (NSCLC). Proc ASCO 2003;Abstract 6.

Miller VA et al. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. Proc ASCO 2004;Abstract 7061.

Perez-Soler R et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22(16):3238-47. Abstract

Price N, Belani C. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial. Clin Lung Cancer 2005;6(4):214-6. No abstract available

Saltz L et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc ASCO 2003;Abstract 817.

Shepherd FA et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc ASCO 2004;Abstract 7022.

Shepherd FA et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18(10):2095-103. Abstract

Strauss GM et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc ASCO 2004;Abstract 7019.

West H et al. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Proc ASCO 2004;Abstract 7014.

Winton TL et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. Proc ASCO 2004;Abstract 7018.